Leaders from Top Pharmaceutical Companies, Innovating the Future of Drug Discovery.
The 2026 event brings together scientific leaders and innovators from the world’s top pharmaceutical companies to share groundbreaking research, real-world insights, and emerging strategies across drug discovery. Explore presentations from industry experts driving advances in areas such as AI/ML, targeted protein degradation, fragment-based discovery, peptide therapeutics, and more.
Integrated Hit Discovery for DNPH1: Applying Multiple Hit-Finding Platforms to Tackle a Challenging Oncology Drug Target
Ben Whitehurst, PhD, Associate Principal Scientist, AstraZeneca
Proximity Binding Assay for PROTAC Ternary Complex Analysis
Goran Dahl, PhD, Associate Principal Scientist, Biophysics, AstraZeneca
Direct-to-Biology for WRN-Targeted Covalent Hit Identification and Optimisation
Sam M. Rowe, PhD, Investigator, Chemical Biology, GSK
Fragment-Based Discovery Establishes Ligandability of the Transcription Factor MITF
Jürgen Hinrichs, PhD, Senior Principal Scientist, GDC Oncology, Novartis Biomedical Research
DELT at Roche
Eleonore Schmidt, PhD, Scientist, DNA Encoded Library Technology, F. Hoffmann-La Roche Ltd.
Panel Discussion: How are AI/ML Techniques Impacting Drug Discovery in Pharma?
Panelist: Anders Hogner, PhD, Senior Director, Head of Computational Chemistry CVRM, AstraZeneca R&D
Co-Folding Application in Compound Optimisation: Impact on DMTA Cycle Reduction
Jose Carlos Gómez-Tamayo, Principal Scientist, CADD, Johnson & Johnson Innovative Medicine
Computational Strategies for Degrader Discovery & Optimisation
Christin Rakers, PhD, Principal Scientist, Computational Chemistry, Discovery & Development Technologies, Merck Healthcare KGaA
PROTACs in Respiratory Disease: Opportunities for Inhaled Delivery
Lena Ripa, PhD, Director, Medicinal Chemistry, AstraZeneca
TRIM21 E3 Ligase as a Platform for PROTACs and Molecular Glues
Markus Queisser, PhD, Scientific Director, Protein Degradation, GSK
Tackling Intrinsically Disordered Proteins: A Novel Peptide Disrupting the p53–FOXO4 Interaction
Carina A. Johansson, PhD, Associate Principal Scientist, Cell Protein & Structural Chemistry, AstraZeneca
Identification and Optimisation of Fragment-Derived and DEL-Truncated Inhibitors Targeting Novel Allosteric Sites on WRN Helicase
Justyna Sikorska, PhD, Associate Principal Scientist, Mass Spectrometry & Biophysics, Merck